Good day, and welcome to the Co-Diagnostics First Quarter 2021 Earnings Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. Please go ahead.

Thank you. I'm Andrew Benson, and joining me this afternoon are members of the Co-Diagnostics management team, including Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. We will begin the call with management's prepared remarks and then open up the call to questions from our analysts. Before we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during the course of this call may constitute forward-looking statements. Any statement about company expectations, beliefs, plans, objectives, assumptions of future events or performance are forward-looking statements. For example, statements concerning 2021 financial operational guidance, the development, regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward-looking statements. The company believes these statements are based on reasonable assumptions. However, these statements are not guarantees of performance and involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. Important factors, which could cause actual results to differ materially from those in these forward-looking statements are detailed in Co-Diagnostics filings with the SEC. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. In addition, the company will discuss certain non-GAAP financial measures during today's call. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release out shortly before this call, which contains reconciliation to the non-GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co-Diagnostics, Chief Executive Officer, Dwight Egan. Dwight?

Thank you, Andrew, and thank you all for joining us. On this call, we will provide an overview of our results for the quarter, updates on key financial performance metrics, and a discussion of progress and future strategy. Then we will take questions from our analysts. We are very enthused about the performance of Co-Diagnostics during the first quarter. The positive impact we've been able to have in various regions and the value we've been able to provide to our shareholders. We would like to thank our employees for their dedication and actions that delivered outstanding results for the quarter. We are also excited about the continued progress the company has made so far in Q2. Sales of our tests continued to be strong in both domestic and international markets. Overall sales momentum is continuing to be consistent with prior quarters since the pandemic began. As expected, demand for our Logix Smart COVID-19 tests continued to drive sales. We anticipate demand for our portfolio of products to continue as we remain well positioned to be a leading global molecular diagnostics company. As we forecast during our first quarter call, we expected the revenue mix to trend more toward the international markets as 2021 progressed. The Q1 domestic-international revenue mix was essentially equivalent to prior quarters. As predicted in our last call, we are seeing some trending towards international sales in Q2, but as stated earlier, overall sales momentum has remained stable. The company's ability to maintain consistent sales even as vaccination in the U.S. moves along is the result of several factors including our more durable business model, comprising a large number of distributors and customers in over 50 foreign markets and a broad-based network of CLIA Lab customers in the U.S. The general sentiment in the U.S. is relieved as vaccination rates rise, but meanwhile the world as a whole is experiencing its highest level of infections since the pandemic began, seeing surges in cases and deaths in some countries. This means that new mutations, variants and strains are evolving that may compromise the worldwide situation. Keep in mind that vaccination in the United States has just crossed through one-third of the country being fully vaccinated, but on a worldwide basis, that equals less than 1.5% of the earth's population. Worldwide, only about 4% of the population is vaccinated. India is at 2% to 3%, and many countries have no material access to vaccines. That is why we have always agreed with Dr. Michael Osterholm, a member of the President's COVID-19 Task Force, who said we're not going to be vaccinating our way out of this to eight plus billion people in the world right now. According to The New York Times yesterday in the U.S., more than 600 people die from COVID each day on average. India's death toll has been horrific. Cases have been rising in Cambodia, Malaysia, Thailand, and Brazil, and much of South Africa and South America are struggling too. All of these serve as reminders that the world remains vulnerable to new waves. Suffice it to say that the worldwide incidence of COVID-19 infection is currently more prevalent than at any other time during the pandemic. In the United States, a great deal of political and media attention has been directed to the status of vaccinations in the country. But notwithstanding the great efforts to curtail COVID-19 through mass vaccination, the level of infection in the U.S. is still on par with what we were experiencing at the beginning of last summer, which as listeners may recall, was deemed to be a very serious situation in every region of the country. Moreover, as previously mentioned, worldwide, we are experiencing more COVID infections than we have ever had before. In other words, the political and media focus on vaccination progress in the United States is masking the true prevalence of COVID-19 cases around the world and, to some extent, in the United States as well. So to be clear, let me reiterate, sales remain strong, and our domestic and international distribution model is proving to be a durable and diverse business model. These conditions are providing the cash flow for Co-Diagnostics to increase the number of markets we serve and to more fully develop the capabilities of our powerful and unique intellectual property, which we are about to leverage in significant and far-reaching ways over the next several quarters and in the years to come. Turning to the normalization of society, we believe that many organizations will develop testing protocols to promote the safety of their employees and customers as normalization is attempted in countries where vaccination is more prevalent. For example, restaurants will want to inform patrons that the staff is tested regularly, so the transmission resulting from close contact with a server and diner is minimized. In a recent survey, two-thirds of participants said they would rather quit than return to the workplace, with more than half citing COVID as the primary reason. Businesses want to provide a COVID safe work environment for employees and also desire to avoid potential legal liability for negligence claims that may arise if prudent regular testing protocols are ignored and employees, customers, or their families become sick or potentially die from COVID exposure while at work. Obviously, airlines, cruise ships, theme parks, and entertainment venues are also concerned about ensuring COVID safe conditions for their employees and customers. Over the last 16 months, our primary concern has been to supply test kits around the world, doing our part in the ongoing development of several new innovations for mass-scale testing, as well as point of care and at-home applications that are in wide use around the world. For example, in conjunction with some of our capable partners such as Clinical Reference Laboratory, one of the largest privately held clinical testing laboratories in the U.S., new PCR science and technology pioneered by the company and CRL is enabling and expanding the applications and accessibility of PCR tests, including non-invasive and highly accurate saliva PCR tests for at-home collection. In November, CRL announced that it is selling its CRL rapid response saliva-based COVID-19 RT-PCR test directly to consumers. In February of this year, CRL and Walgreens announced that the FDA authorized the CRL rapid response COVID-19 saliva test based on Co-Diagnostics' CoPrimer technology, which is now available through Walgreens' Fin Care, a digital health platform available on the Walgreens app and walgreens.com, offering consumers the convenience of self-collecting the test right in their own homes without supervision. The CRL announcement states that the test uses CoPrimer probes and primers developed by Co-Diagnostics, with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting with results typically delivered within 24 hours via a secure online platform. While we observe the daily infection and death counts around the world, we are also, of course, able to monitor the daily influx of demand for our tests, which now includes several different variations of our COVID assays and several different modes of sample collection and instrumentation. The strong level of orders has not abated, and we believe the expected shift of geographic emphasis trending towards our international clients reflects the lack of vaccination combined with mutations and more pernicious variants, or other causes, which have resulted in infection and death that is off the charts in some countries such as India and Brazil. Just how long the virus continues to run somewhat unchecked in certain areas of the globe, we cannot say. But if our order flow for tests is an indication of the world's predicament, we potentially have a long way to go before the world is COVID safe. Additionally, much attention is being placed on normalization in the developed world, including the United States. To be sure, this is still in its infancy, and a significant amount of ongoing and regular testing is likely to be needed to create COVID safe work environments, safe schools, safe restaurants, and safe travel and sports venues. Since cold and flu symptoms mirror COVID-19 in the initial stages, people potentially infected with COVID will need differentiation tests. Our ABC test, for example, has traversed from comprising 1% of fourth-quarter testing orders to 5% in Q1 and 14% so far in Q2. We will continue to supply the United States with critical PCR tests as normalization is attempted, and we will also continue to supply a significant number of tests to international customers, who are comparatively a long way from COVID safety and far behind the U.S. with respect to vaccinations. India is only at 2% to 3% vaccination levels, and Africa is only at approximately 1%. That's how we see the current environment. I will now turn to a discussion of the Eikon testing platform, which we regard as the most important of all our inventions and technologies, and represents the combination of a herculean effort on the part of the company, as well as other world-renowned experts who are involved in its development. The Eikon platform includes several breakthrough technological advancements. Its unique chemistry includes Co-Diagnostics' flagship patented CoPrimer molecules in a lyophilized or freeze-dried reagent that is activated with the company's direct saliva extraction pre-protocol. CoPrimers virtually eliminate cross-reactivity, enabling multiplex assays with a high level of accuracy. The device is being developed by trailblazing real-time PCR scientists who are renowned for previous PCR-based inventions, which are currently in widespread use around the world by prominent entities including Roche and the U.S. government. The Eikon device is designed to deliver accurate COVID-19 PCR results in less than 30 minutes from patient direct saliva samples which do not require extraction. A simple saliva sample is placed into a disposable receptacle, which is then inserted into the compact platform, and a command from a smartphone app starts the test. The smartphone app displays the progress of the test, concluding with the result in about 30 minutes. Additional cloud-based data applications facilitate multiple paths for data distribution to appropriate parties. There are several global trends that motivated Co-Diagnostics to create the new platform. First and foremost is a long-term need for molecular testing that is inexpensive, providing fast results in at-home, point of care, and remote locations. And just as important, providing results that are accurate. We believe Co-Diagnostics' Eikon platform will meet the critical imperative for at-home and point of care locations that need to be addressed during the pandemic. But the Eikon aspirations go far beyond COVID. Indeed, it is designed to cover any RNA or DNA pathogen for which the company develops an extraction-free test. As the unstoppable trend in healthcare moves rapidly towards decentralized healthcare locations, including telemedicine, patients will want faster diagnoses than ever before. However, the results have to be reliable, and test costs need to be inexpensive, among other considerations. Taking all of this into account, including the evaluation of early entries hoping to fill this need, Co-Diagnostics embarked on the most significant development project in its history to create what we believe will be one of the most significant diagnostic advancements ever engineered for worldwide healthcare. We believe the ramifications of this development will be widespread and pervasive. The company has been vigorously pursuing the Eikon development and we are very aware of competitive offerings seeking to attract the same vast market that we envision. But it is one thing to be first and another thing to be right. Co-Diagnostics believes it will be the first company to get it right as we move forward in introducing this brilliant new diagnostic platform. By getting it right, we mean that the Eikon platform will be a very low-cost fully integrated sample-to-result molecular diagnostic platform designed to meet all three criteria of inexpensive, fast, and accurate testing, positioning the company to revolutionize molecular testing in a way that could drive Co-Diagnostics' results for many years to come. Traditionally, molecular testing has been a complicated process that involves numerous steps. These steps include extraction, amplification, detection, interpretation, and reporting results. Because of the complexity of the process, sophisticated, often centralized labs with trained personnel using expensive equipment were required to process the test. In contrast, the Eikon platform, through a combination of unique and powerful technologies and innovations, will be able to complete all necessary steps in a sample-to-result mode with almost no human interaction. Besides spitting into a small container, placing the container into the compact device, and activating the test through a smartphone app, the user can then walk away while the system provides rapid results through the smartphone app. The progress that has been made on the device in a relatively short amount of time is truly staggering. We anticipate being able to provide updates on the validation and timeline for an application with the FDA for emergency use for the device and the initial test by the next earnings call, as well as our more long-term expectations for additional regulatory clearance and updates on the planned menu for the platform. The key to getting it right is not just for the short-term; it is rather a long-term strategy that can replace antigen testing because it has all of the primary benefits of antigen tests: low-cost, rapid testing at home and point of care locations, while also delivering gold standard PCR accuracy as opposed to the less accurate antigen testing. Over the next several years, the company expects to conduct sales campaigns to a vast number of potential clients, which include doctors' and dentists' offices, schools and college campuses, theme parks, airlines, cruise ships, sports venues, restaurants, and others. We believe the overall value proposition of this product has the potential to leapfrog over diagnostic systems currently in place, as well as open up the at-home and point of care markets in ways not previously addressed by other less nimble technologies. From the creation of the CoPrimers technology to the engineering of this device, to the human factor studies and focus groups to the regulatory team, this product development represents a high level of innovation, expertise, and skill sets, which together portend a successful future for the product and the company as a whole. Let me now turn things over to Brian Brown, our CFO, for a review of the key financial metrics and numbers, after which I will conclude with a discussion of future plans outside of what has already been discussed here. Brian?

Thanks, Dwight. For the quarter, revenue increased to $20.0 million from $1.5 million from the prior year first quarter, primarily due to continued sales of the Logix Smart COVID-19 test. Gross profit increased from $1.1 million in the first quarter of 2020 to $16.8 million in the first quarter of 2021, representing 83.7% of consolidated revenue, due to improved product mix, as compared to the prior year period. Total operating expenses for the quarter, inclusive of corporate, general and administrative, sales and marketing, research and development, and depreciation and amortization, increased $4.3 million from $2.1 million in the first quarter of 2020 to $6.4 million dollars in the first quarter of 2021, primarily driven by overall business activities, resulting from our increase in revenue and investment in people, processes, and research and development. Income from operations for the first quarter improved to $10.3 million versus an operating loss in the prior year quarter due to continued strong revenue and gross profit. We achieved income before taxes of $9.9 million compared to a loss of $1.1 million in the prior year comparative quarter. As for income taxes, for the three months ended March 31, 2021, we recorded an income tax expense of $2.0 million, representing a corporate effective tax rate of 20.1%. We achieved net income for the first quarter of $7.9 million, or $0.26 per fully diluted share, compared to a net loss of $1.1 million in the prior year first quarter, which was primarily the result of sales of our Logix Smart COVID-19 test and resulting margins from those sales offset by increased operating expenses and corporate income taxes. Turning now to our balance sheet and liquidity, our balance sheet remains strong, allowing us to invest in additional growth opportunities. As of March 31, 2021, cash, cash equivalents, and marketable securities totaled $60.1 million, an increase of $12.8 million from December 31, 2020. We continue to remain well capitalized with no debt and a strong cash position that has afforded us financial flexibility as we execute our Strategic Growth Plan, which includes investment in our people, processes, and research and development. While we anticipate increased expenses in the second quarter of 2021, we expect our cash balance to continue to grow with no debt. We ended the quarter generating $12.3 million in cash from operations, which represents an improvement of $13.6 million over the prior year quarter's use of operating cash of $1.3 million. This significant increase in cash flow from operations is a testament to the hard work of our people and the continued improvement of our processes. Now turning to our guidance for the second quarter of 2021, we anticipate revenue for the quarter totaling between $20.0 million and $22.0 million due to continued strong demand for our products. Including expected R&D spending on our new diagnostics platform, we anticipate diluted earnings per share between $0.19 and $0.23 based on 30 million shares outstanding and a corporate effective income tax rate of approximately 21.0%. As noted previously, we remain confident in our ongoing profitability and will continue to invest in our growth. We are expanding our international footprint as sales continue to increase abroad. We are building upon our solid business foundation and are in a strong position to continue progressing the company forward. We continue to innovate and leverage our technologies in order to scale and develop other necessary testing, which will allow us to more quickly enter markets while staying focused on our long-term growth strategy.

Thank you, Brian. Our international footprint continues to grow as sales increase, and we believe that this fact sets Co-Diagnostics apart from many other participants in the COVID-19 testing space. Our distribution model is diverse, with multiple distributors covering over 50 countries. This means we are not limited to the traffic generated to a few CLIA Labs by limited numbers of mass testing sites. Our customer base is worldwide, which is currently experiencing high levels of infection along with low levels of vaccination. Our PCR test, in contrast to antigen tests, is even more important as the overall value proposition of less sensitive technologies diminishes. We are confident in Co-Diagnostics' growing portfolio of molecular diagnostics products, and we will continue to leverage our CoPrimer technology platform as we scale up that menu, allowing us to provide more products to more markets even faster. Key among these anticipated products are those within our liquid biopsy vertical, which we anticipate playing a significant role as part of our growth strategy. We believe that liquid biopsy testing for cancer and cancer treatment monitoring is the future of cancer detection. The global market as a whole is expected to grow from just over $1 billion in 2019 to over $5 billion in 2027. As more hospitals, labs, and physicians adopt liquid biopsy as the standard for cancer detection and monitoring. The company is pleased with the results that we have been seeing during the development process for liquid biopsy products built on the CoPrimer platform, and we anticipate being able to provide technology and development updates for this vertical soon. The company regards this expanded international presence as a considerable asset, not only for our existing COVID-19 suite of diagnostics, including our ABC and direct saliva tests, which continue to see increasing sales, but for the other products planned and in development. Among these products include diagnostics for hepatitis B and hepatitis C, the combined global market size for which is estimated to grow to nearly $7 billion by 2025. Nearly every single international customer or distributor, along with several domestic customers, has expressed interest in these tests once developed and brought to market. This is similarly true for human papillomavirus and HIV diagnostics, with respective global market sizes of over $1 billion expected in 2025 and $4.9 billion expected in 2023. With growing global markets and ready-made customers for these diagnostics, the value of our growing network of distributors and customers becomes apparent. Other tests currently in development include those for RSV, our malaria test that uses our novel CoPrimer technology to differentiate between species of the parasite that might be resistant to certain treatments, and an STI panel for gonorrhea and chlamydia, among others. Aside from these products, our vector control vertical is also showing growth this year, with some of our largest orders of tests received to date. There are relatively few diagnostics companies developing and marketing tests to this largely unaddressed customer base. Our revenue from the segment is entirely domestic. Since our Vector Smart products are not used for human diagnosis, we are able to offer these tests throughout the country without an EUA 510(k) clearance or other premarket authorization from the FDA. Additionally, we continue to develop our agricultural vertical, which is supported by strong partnerships and customer relationships with companies like LGC, Biosearch, and Bayer. With regards to India, we believe that the country's approach to testing in the latter part of 2020 and the first quarter of 2021 failed to reflect the seriousness and danger of COVID-19. As a result, CoSara experienced a monetary loss in both of the last two quarters. The current surge of cases and deaths that is plaguing the country has brought with it a renewed focus on the importance of accurate, reliable, affordable, high throughput PCR testing, exactly the kind of support that CoSara has been well positioned to provide. As a result, so far this quarter, the joint venture is experiencing a dramatic uptick in the number of tests sold. Even before the pandemic began, India had been poised to become the largest healthcare market on the planet, and its high infectious disease burden has made the country an area of focus for Co-Diagnostics since even before we established the CoSara Diagnostics joint venture. These factors, along with the quality of our joint venture partners and state-of-the-art manufacturing facility, have contributed to making India a critical component of the company's long-term strategy, especially in that region of the world. Keep in mind that it has never been more important to ensure that we are having maximum positive impact in a region where we are able to help as many people as possible, which includes pricing our products at prices that can be supported by the market. However, each new customer and distributor with whom we forge a solid relationship during the pandemic enlarges our footprint and will afford even more future opportunities related to the healthcare market for other eventual products. The joint venture's dedication to the Indian people in providing quality real-time PCR tests has expanded territory to about 160 current customers, which includes equipment installation and 73 laboratories, over 40 of which did not have access to PCR technology prior to becoming CoSara customers. The joint venture is already awaiting the export quota to be assigned for additional tests for the surrounding Asia Pacific, African, and Middle Eastern territories, and is in the process of applying for CE-IVD clearance for several of its products. 2020 was truly an inflection point for Co-Diagnostics, illustrating our ability to successfully and profitably develop and bring high-quality diagnostic products to the market, and our upcoming menu that I described previously illustrates that our near and long-term growth plans will allow us to continue to operate profitably in the future, independent of revenue derived from our primary COVID test. We are already seeing our CE mark ABC test for influenza and COVID-19 begin to replace orders for the standalone COVID-19 test, a fact which we believe is indicative of the direction COVID testing is going as the disease becomes endemic in many parts of the world and bodes well for our continued foothold in the respiratory diagnostic space. But it is important not to lose sight of the fact that the need for COVID-19 diagnostics remains strong at the present time. The demand for our menu of COVID tests seems to indicate the need for continued testing domestically and especially internationally, despite widespread vaccination in the U.S. and certain other more developed countries. That concludes our prepared remarks. Operator, we are ready to begin the question and answer portion of the call.

Our first question comes from Yi Chen with H.C. Wainwright. Please go ahead.

Thank you for taking my questions and congratulations on a solid quarter. My first question is, is CoSara's operation in any way negatively impacted by the pandemic in India?

Yes, Yi, thank you for that question with respect to CoSara. Our laboratory in CoSara, in India, was the very first laboratory in the country to receive permission to make a COVID-19 test. As you know, during 2020, we experienced a robust testing sales environment throughout India. As I mentioned in my prepared remarks, during the last couple of quarters, India basically dropped the ball on testing, which has resulted in a devastating environment in that country.

I'm actually asking what I'm not actually asking for the output, I'm asking if the operation itself, whether the personnel are affected by the COVID-19?

Okay, good question. The operation is operating just fine. Yi, there were periods of time when they had lockdowns that affected people's ability to come into the lab. But I wouldn't say that those types of things have hampered the ability of the company or joint venture to meet its demand for tests.

And the second question is, do you expect to maintain the gross margin demonstrated in the first quarter going forward?

Yes, Yi, this is Brian. Yes, we are able to do that, though we do expect some pricing pressures as we move forward a bit in some countries. But we expect to maintain a similar gross margin going forward.

Our next question comes from Jason McCarthy with Maxim Group. Please go ahead.

Everyone, thanks for taking my question. It's Dave on the line for Jason. So as COVID continues to be a problem in other parts of the world outside of the U.S., like you mentioned in your prepared remarks, do you foresee the export of COVID tests to ex-U.S. territories? Do you foresee that being a major revenue driver in 2021? And my second question is it's kind of in a similar vein, are you considering any other potential partnership opportunities outside of the U.S. similar to the CoSara joint venture?

Thank you for the question, Jason. Our international business is very strong, and we anticipate it to continue to grow. As we mentioned on our call last quarter, where we had about a 60/40 U.S.-international mix in revenues, we expected that to flip over during 2021 into a 40% domestic, 60% international mix, and I think it's safe to say we are seeing a gradual move in that direction. The first quarter didn't really show that; it was pretty much aligned with what we had expected and experienced in the past. But as we move into the second quarter, we are seeing heavy movement into the international markets along the lines of what we would expect in that 40/60 move. I’m very enthused about how we have established a presence in 50 countries with some terrific distributors, and the need for our tests—not just our initial COVID test, but our COVID Version 2 that has more than one target in the genome, and also our ABC test and our saliva test—are all things that are helping to increase our market share overseas. With respect to your second question concerning partnerships outside of the country, currently, we don't have any relationships outside of the country that we're exploring regarding a joint venture of the nature that we have with CoSara. We established the CoSara joint venture several years ago because we identified India as potentially the largest healthcare market in the world, which I think it will become, and is becoming. So that was the reason we established a presence there. A number of other large companies have also moved into India with manufacturing facilities for all types of pharmaceutical needs. So we believe that was a prudent move that we made in India. As I mentioned, we've got a pretty strong customer base there now with about 160 customers and about 73 different labs now using our products, and we’re ready to give them a much broader menu. Let me just touch on one of the things, Jason, we're talking about what we are providing in terms of COVID testing, hepatitis B, and hepatitis C within regular complex laboratory settings conducting PCR. And I know you're an expert in that field and understand how testing is done, and you also know about our CoPrimers and what is unique about that technology. But it's important to realize that with our forthcoming Eikon platform, which is going to be a very low-cost device with low-cost tests that do PCR, real-time PCR in less than 30 minutes, it is a very unique product—nothing like it in the world today, as far as we know. This product will, in our view, explode from a market standpoint, in places like India where you have numerous labs. But many of them we wouldn’t call labs by our standards, but with the availability of something like the Eikon product, the number of labs that can suddenly get into the molecular diagnostics business will significantly increase, enabling people in rural areas of India to access testing without having to travel to bigger cities. I think that gives a clear idea of how far-reaching and revolutionary our new Eikon platform is going to be.

Our next question comes from Theodore O'Neill with Litchfield Hills Research. Please go ahead.

Thank you, and congratulations on the good quarter. Dwight, I was wondering, so this Eikon testing platform, is this basically a lab in a box that I'm going to have at home?

I think that's not a bad way to characterize it. It's a very small device, about 4.5 to 5.5 inches square. This was featured not too long ago on NBC's Today Show, where they were showing what kind of things are likely to happen as people return to work in the United States, and they highlighted our Eikon device and demonstrated how it would be used and how simple it is to use. The important thing about it is that it accepts a direct saliva or nasal swab sample from the patient, which is self-administered. It just goes right into the little box. You close the box, and then you use a cell phone app to activate the test and start it. You can then walk away, return to your work or whatever you were doing in your home while the results come to you in less than 30 minutes. Of course, because of the Bluetooth connectivity and connectivity into the cloud, all the data distribution points for public health and other reasons can also be accommodated. What makes this device really unique are a few things, but one is the fact that it doesn't require extraction to get to the pathogen. That has made it groundbreaking as this has not happened before in the world of molecular diagnostics, which typically requires very sophisticated labs. We’ve managed to take it out of that environment by eliminating the need for extraction, which is very unique and significant, along with lyophilizing our product and developing this device with world-renowned experts in rapid PCR.

You've got a lot of cash on the balance sheet now; is there any thought about giving shares back or buying back shares?

We don't have any thoughts about that right now. We have a lot of cash, and we've been able to finance our operation and our significant R&D, especially with respect to the Eikon product. We're focused on creating value for our shareholders, and anything that would enhance that is something we will consider, but for now, I think the best way for us to proceed is to keep our heads down and execute on the delivery of this Eikon product with the associated test menu. We think this is truly a revolutionary product, and we're excited about its launch. We firmly believe we need to retain cash reserves for maximum flexibility as we get this product ready for the market both domestically and internationally.

This concludes the question and answer session. I would like to turn the conference back over to Dwight Egan for any closing remarks.

Thank you. Since the beginning of the pandemic, it's been difficult to accurately predict how much impact COVID-19 will have on Co-Diagnostics in the long term. For us, the disease provided a gateway to introduce our CoPrimer technology platform and suite of high-quality PCR products to a far wider audience and to do so substantially faster than would have been imaginable before 2020. What I hope I've been able to illustrate today is that while we do believe sales directly related to COVID are expected to remain strong in the short and medium term, our long-term prospects are even more exciting than anything we have experienced to date. This performance will be driven by a substantially increased suite of molecular diagnostics for established customers and distributors in growing domestic and international markets, becoming a key player in the cancer detection space, and most importantly, our entrance into the molecular diagnostics device market with the Eikon platform. Thank you to all of you for your interest in our company, our analysts, and our shareholders. Thanks for joining us today on our first quarter call. We look forward to talking with you again after the second quarter.

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.